Goodwin B L, Xi H, Tejiram R, Eason D D, Ghosh N, Wright K L, Nagarajan U, Boss J M, Blanck G
Department of Biochemistry and Molecular Biology, College of Medicine and Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA.
Cell Growth Differ. 2001 Jun;12(6):327-35.
Melanoma cells commonly express MHC class II molecules constitutively. This is a rare, or possibly unique, phenotype for a nonprofessional antigen-presenting cell, where MHC class II expression ordinarily occurs only after IFN-gamma treatment. Despite the fact that constitutive expression of MHC class II on melanoma cells has been observed for decades and that the regulation of the MHC class II genes is well understood for many different cell types, there is no data regarding the basis for constitutive MHC class II expression in melanoma cells. Here we report that MHC class II expression in melanoma cells can be traced to constitutive expression of the class II transactivator protein (CIITA), which mediates both IFN-gamma-inducible and -constitutive MHC class II expression in all other cell types. In addition, we determined that constitutive CIITA expression is the result of the activation of both the B cell-specific CIITA promoter III and the IFN-gamma-inducible CIITA promoter IV, the latter of which previously has never been known to function as a constitutive promoter in any cell type. The recently described B cell-related ARE-1 activity is important for promoter III activation in the melanoma cells. Constitutive promoter IV activation involves the IFN regulatory factor element (IRF-E), which binds members of the IRF family of proteins, although the major, IFN-gamma inducible member of this family, IRF-1, is not constitutively expressed in these cells. In cells with constitutively active promoter IV, the promoter IV IRF-E is most likely activated by IRF-2. The relevance of these results to the pathway of melanoma development is discussed.
黑色素瘤细胞通常组成性表达MHC II类分子。对于非专职抗原呈递细胞而言,这是一种罕见的,甚至可能是独特的表型,因为在非专职抗原呈递细胞中,MHC II类分子通常仅在γ干扰素处理后才会表达。尽管黑色素瘤细胞上MHC II类分子的组成性表达已被观察到数十年,并且对于许多不同细胞类型,MHC II类基因的调控已被充分了解,但关于黑色素瘤细胞中MHC II类分子组成性表达的基础尚无相关数据。在此我们报告,黑色素瘤细胞中MHC II类分子的表达可追溯到II类反式激活蛋白(CIITA)的组成性表达,CIITA在所有其他细胞类型中介导γ干扰素诱导的和组成性的MHC II类分子表达。此外,我们确定组成性CIITA表达是B细胞特异性CIITA启动子III和γ干扰素诱导性CIITA启动子IV激活的结果,其中后者此前从未被发现在任何细胞类型中作为组成性启动子发挥作用。最近描述的与B细胞相关的ARE-1活性对于黑色素瘤细胞中启动子III的激活很重要。组成性启动子IV的激活涉及干扰素调节因子元件(IRF-E),它可结合IRF蛋白家族的成员,尽管该家族中主要的、γ干扰素诱导性成员IRF-1在这些细胞中并非组成性表达。在具有组成性活性启动子IV的细胞中,启动子IV的IRF-E很可能被IRF-2激活。本文讨论了这些结果与黑色素瘤发展途径的相关性。